A Phase 1 interventional study of Placebo and MEDI8897 10 mg in Respiratory Syncytial Virus, sponsored by MedImmune LLC. Completed at 13 sites in 3 countries. Open to participants aged Up to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-19.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.
This Phase 1b/2a study will be a dose-escalation design to begin data collection on PK and safety in children. The population to be enrolled is healthy preterm infants born between 32 weeks 0 days and 34 weeks 6 days gestation who would not receive RSV prophylaxis based on the American Academy of Pediatrics (AAP) or other local guidelines. These subjects will not be receiving palivizumab, allowing for a placebo comparator group to begin collecting data on incidence rates of RSV medically attended lower respiratory illness (MA-LRI) and efficacy. Enrollment is planned at approximately 20 sites in the USA, Chile, and South Africa.
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted after MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants will receive placebo intramuscularly.
Drug: Placebo
Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
Drug: MEDI8897 10 mg
Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
Drug: MEDI8897 25 mg
Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Drug: MEDI8897 50 mg
Participants will receive placebo intramuscularly.
Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity of a participant who received MEDI8897. TEAEs and TESAEs were the events that occurred between administration of study drug (Day 1) and Day 361 that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Number of Participants With Treatment-Emergent Adverse Events of Special Interest
An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator (that is, within 24 hrs of knowledge of the event) to the sponsor. The AESIs for this study were hepatic function abnormality meeting the definition of Hy's law, hypersensitivity reactions including anaphylaxis, immune complex disease, and thrombocytopenia. Treatment-emergent AESIs were collected from the time of dosing until Day 361 post-dose.
Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361)
Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events
Laboratory abnormalities determined by the investigator to be clinically significant that occurred after study drug dosing through 151 days post-dose that were absent before treatment or that worsened relative to pre-treatment state were reported as TEAEs. Laboratory evaluations (haematology and serum chemistry) of blood samples were performed.
Time frame: From Study Drug Administration (Day 1) Through the Follow-up Period (Day 151)
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897
The Tmax defined as time at which maximum observed concentration of MEDI8897 (Cmax) was observed.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Maximum Observed Serum Concentration (Cmax) of MEDI8897
The Cmax is the maximum observed serum concentration of MEDI8897.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897
Area under the concentration-time curve of the MEDI8897 in serum over the time interval from day 1 to day 151 (AUC1-151).
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), and 150 (± 7) Post-dose
Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897
The pharmacokinetic (PK) parameter AUC (0-infinity) was estimated based on the serum concentrations of MEDI8897.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Terminal Elimination Half Life (t1/2) of MEDI8897
Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Extravascular Clearance (CL/F) of MEDI8897
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Extravascular Volume of Distribution (Vz/F) of MEDI8897
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 7 (± 1), 30 (± 5), 150 (± 7) and 360 (± 7) Post-dose
Number of Participants Positive for Anti-Drug Antibodies to MEDI8897
A participant was considered ADA-positive if the participant had a positive reading at any time point post baseline. Titers greater than or equal to 50 were considered positive.
Time frame: Pre-dose at Baseline (Days -7 to -1) and on Days 31, 151, and 361 Post-dose
Participants were recruited between January 2015 and September 2015 at 10 sites (USA, South Africa, and Chile) and followed for 1 year after dosing.
| Milestone | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Started | 18 | 8 | 31 | 32 |
| Completed | 16 | 8 | 31 | 30 |
| Not completed | 2 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 1 |
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity of a participant who received MEDI8897. TEAEs and TESAEs were the events that occurred between administration of study drug (Day 1) and Day 361 that were absent before treatment or that worsened relative to pre-treatment state.
| Participants | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| TEAEs | 17 | 5 | 31 | 30 |
| TESAEs | 0 | 0 | 1 | 2 |
An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator (that is, within 24 hrs of knowledge of the event) to the sponsor. The AESIs for this study were hepatic function abnormality meeting the definition of Hy's law, hypersensitivity reactions including anaphylaxis, immune complex disease, and thrombocytopenia. Treatment-emergent AESIs were collected from the time of dosing until Day 361 post-dose.
| Participants | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events of Special Interest | 0 | 0 | 0 | 0 |
Laboratory abnormalities determined by the investigator to be clinically significant that occurred after study drug dosing through 151 days post-dose that were absent before treatment or that worsened relative to pre-treatment state were reported as TEAEs. Laboratory evaluations (haematology and serum chemistry) of blood samples were performed.
| Participants | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Anaemia | 6 | 0 | 8 | 4 |
| Microcytic anaemia | 0 | 0 | 0 | 3 |
| Neutropenia | 0 | 0 | 0 | 1 |
The Tmax defined as time at which maximum observed concentration of MEDI8897 (Cmax) was observed.
| Day | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI8897 | 7.04 ± 0.0683 | 7.04 ± 0.394 | 6.93 ± 0.549 |
The Cmax is the maximum observed serum concentration of MEDI8897.
| microgram per milliliter (mcg/mL) | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of MEDI8897 | 23.2 ± 9.28 | 30.9 ± 10.4 | 71.7 ± 15.9 |
Area under the concentration-time curve of the MEDI8897 in serum over the time interval from day 1 to day 151 (AUC1-151).
| Day*mcg/mL | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Day 1 to Day 151 (AUC [1-151]) of MEDI8897 | 1940 ± 809 | 2260 ± 881 | 5470 ± 1440 |
The pharmacokinetic (PK) parameter AUC (0-infinity) was estimated based on the serum concentrations of MEDI8897.
| Day*mcg/mL | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI8897 | 2450 ± NA | 4320 ± 1070 | 7510 ± 1870 |
Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum.
| Day | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Terminal Elimination Half Life (t1/2) of MEDI8897 | 72.9 ± NA | 66.2 ± 7.83 | 62.5 ± 9.35 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.
| mL/day | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Extravascular Clearance (CL/F) of MEDI8897 | 4.08 ± NA | 6.05 ± 1.31 | 7.01 ± 1.57 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
| mL | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|
| Extravascular Volume of Distribution (Vz/F) of MEDI8897 | 429 ± NA | 581 ± 159 | 633 ± 168 |
A participant was considered ADA-positive if the participant had a positive reading at any time point post baseline. Titers greater than or equal to 50 were considered positive.
| Participants | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Baseline | 1 | 0 | 0 | 0 |
| Day 31 | 0 | 2 | 0 | 0 |
| Day 151 | 0 | 0 | 0 | 0 |
| Day 361 | 0 | 1 | 7 | 10 |
Collected over From Study Drug Administration (Day 1) Through the Follow-up Period (Day 361). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 0/18 (0%) | 17/18 (94.4%) |
| MEDI8897 10 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| MEDI8897 25 mg | 0/31 (0%) | 1/31 (3.2%) | 31/31 (100%) |
| MEDI8897 50 mg | 0/32 (0%) | 2/32 (6.3%) | 28/32 (87.5%) |
| Event | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Febrile convulsionNervous system disorders | 0/18 | 0/8 | 0/31 | 2/32 |
| Lower respiratory tract infectionInfections and infestations | 0/18 | 0/8 | 1/31 | 1/32 |
| Event | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 12/18 | 4/8 | 23/31 | 22/32 |
| PyrexiaGeneral disorders | 3/18 | 3/8 | 8/31 | 5/32 |
| BronchiolitisInfections and infestations | 1/18 | 3/8 | 3/31 | 6/32 |
| Otitis mediaInfections and infestations | 4/18 | 3/8 | 7/31 | 5/32 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/18 | 3/8 | 3/31 | 2/32 |
| GastroenteritisInfections and infestations | 4/18 | 2/8 | 11/31 | 8/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/18 | 1/8 | 11/31 | 6/32 |
| AnaemiaBlood and lymphatic system disorders | 6/18 | 0/8 | 8/31 | 4/32 |
| Candida nappy rashInfections and infestations | 1/18 | 0/8 | 9/31 | 2/32 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 3/18 | 0/8 | 9/31 | 3/32 |
The As-treated Population included all participants who received any study drug.
| Age, Continuous(Months) | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 7.0 ± 2.6 | 4.2 ± 2.1 | 6.7 ± 2.7 | 6.9 ± 2.5 | 6.6 ± 2.6 |
| Sex: Female, Male(Participants) | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg | Total |
|---|---|---|---|---|---|
| Female | 11 | 4 | 19 | 19 | 53 |
| Male | 7 | 4 | 12 | 13 | 36 |
| Race (NIH/OMB)(Participants) | Placebo | MEDI8897 10 mg | MEDI8897 25 mg | MEDI8897 50 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 1 | 19 | 21 | 51 |
| White | 4 | 6 | 0 | 2 | 12 |
| More than one race | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 4 | 0 | 11 | 7 | 22 |
Ran from Jan 2015 to primary completion in Sep 2016, 20 months.
Results were first posted in Sep 2018, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab